Bayer AG has confirmed that of the three projects in its Factor XIa program, the full focus is now on the oral treatment asundexian, ahead of two partnered therapies – fesomersen and osocimab – which had also shown potential in mid-stage trials.
Asundexian is positioned as the next-generation Xarelto (rivaroxaban), the firm's blockbuster Factor Xa blood thinner, and Bayer CEO Werner Baumann...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?